Reaction
Axillary Pain reporting signals
As of the last recalculation, Axillary Pain appears in 1,462 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 37.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ado-Trastuzumab Emtansine | 22 | 37.7 | 37.8 |
| Exemestane | 30 | 20.3 | 20.4 |
| Bupivacaine | 10 | 15.3 | 15.4 |
| Ribociclib | 32 | 14.7 | 14.7 |
| Primidone | 9 | 12.7 | 12.7 |
| Pertuzumab | 22 | 11.7 | 11.7 |
| Crisaborole | 7 | 10.4 | 10.4 |
| Letrozole Tablets | 34 | 10.3 | 10.3 |
| Lapatinib | 11 | 10.2 | 10.2 |
| Trastuzumab | 47 | 10.0 | 10.0 |
| Letrozole | 41 | 9.7 | 9.7 |
| Midazolam | 17 | 9.7 | 9.7 |
| Midazolam Hydrochloride | 17 | 9.1 | 9.1 |
| Ozanimod Hydrochloride | 5 | 8.6 | 8.6 |
| Abemaciclib | 10 | 7.2 | 7.2 |
| Etonogestrel | 21 | 6.3 | 6.3 |
| Docetaxel Anhydrous | 26 | 5.6 | 5.6 |
| Docetaxel | 26 | 5.6 | 5.6 |
| Buprenorphine Hydrochloride, Naloxone Hydrochloride | 9 | 5.3 | 5.3 |
| Siponimod | 3 | 4.8 | 4.8 |
| Dabrafenib | 7 | 4.7 | 4.7 |
| Palbociclib | 31 | 4.7 | 4.7 |
| Bimekizumab | 6 | 4.0 | 4.0 |
| Relugolix | 6 | 3.6 | 3.6 |
| Pegfilgrastim | 16 | 2.3 | 2.3 |
| Voxelotor | 3 | 1.9 | 1.9 |
| Tirzepatide | 17 | 1.5 | 1.5 |